Press Room

RDD 2024

Start
Sunday, May 05, 2024
End
Thursday, May 09, 2024
Location: Arizona, United States
Booth Number: 22
RDD 2024 - Hovione

Hovione will be exhibiting at RDD conference from May 5-9. Don’t miss the chance to speak with our experts and learn how our development and manufacturing services for inhalation and nasal - integrated on a single site - can support in bringing your product to market.
 
We are centrally located between the 'Inspiring Dry Powder Inhalation' and 'Nasal Spotlight' Knowledge Space areas.

schedule a meeting

 

 

 

HOVIONE WORKSHOP

Nasal Powders: Enhancing Formulation and Device Synergy
May 7th from 2:00 PM to 6:00 PM 
Presenters: 
Dina Morais, Ph.D. - R&D Senior Scientist, Inhalation and Advanced Drug Delivery
Cláudia Costa, Ph.D. - R&D Scientist, Advanced Analytical Characterization

Access the recorded session here

(Gated content. Registration is required.)

 

Short description: This workshop will address the complexities of formulating nasal powders including achieving the right balance between drug solubility, bioavailability, and delivery by exploring Hovione´s nasal toolbox for formulation strategies and advanced analytical characterization, within the current regulatory framework. The selection of appropriate excipients and manufacturing technologies as well as control over critical process parameters are key factors during product development. The formulation-device dependency when developing nasal products will also be highlighted, focusing on case studies using the new Hovione nasal device.

Key learning: Get to know Hovione´s integrated formulation-device solution for nasal powders development and learn how the early-stage in vitro screening may be predictive of the in vivo nasal powder performance.
 

HOVIONE POSTERS

"Systemic Nasal Absorption of Amorphous Solid Dispersions: Supersaturating Systems for Fast Onset of Action of Poorly Soluble Drugs Through the Nasal Mucosa"
Authors:
Patricia Henriques, Dina Morais, Slavomíra Doktorovová, Ana Fortuna
Presenter: Dina Morais, Ph.D. - R&D Senior Scientist, Inhalation and Advanced Drug Delivery

Poster brief description: The poster shows the potential of amorphous solid dispersions for nasal delivery of a poorly soluble drug, through in vitro, ex vivo and in vivo studies.

Key Learning: Supersaturating systems promote nasal absorption of poorly soluble drugs, leading to faster onset of action. In vitro dissolution and ex vivo permeation methodologies are valuable tools for selecting the best formulations prototypes.

 

"Drug Load Influence on Aerodynamic Properties of High Dosage DPIs: A Case Study of an Aminoglycoside Model Drug"
Authors:
João Pires, Maria Inês Lopes
Presenter: João Pires, Ph.D. - R&D Manager, Inhalation and Advanced Drug Development

Brief description: The study assessed the influence of the drug load on both primary aerodynamic distributions, measured online in the spray-drying process, and the final in vitro performance of carrier-free DPI formulations.
 
Key Learning: The aerodynamic size measurement during the spray-drying process allows the rapid screening of viable formulation candidates, enabling a more straightforward DPI development process.

 

"Differential Permeability of Dry Solid and Aqueous Suspensions of Fluticasone Propionate through A549 Alveolar Epithelial Cells"
Authors:
Alexandre J.S. Ribeiro
Presenter: Alexandre Ribeiro, Ph.D. - R&D Principal Analytical Scientist, Analytical Development

Short description: Determining the lung permeability of orally inhaled drug products with in vitro cell-based platforms has high potential to predict their bioavailability during preclinical studies and increase the success rate of drug development. Cellular platforms used in permeability studies aim to recreate the pulmonary epithelial air-liquid interface barrier, where an inhalable product is deposited onto its apical side and then permeated through a polarized and tight epithelium into its basolateral side. A dry powder fluticasone propionate inhalable formulation was deposited in powder form or suspended in a cellular buffer solution on the apical side of an epithelial culture to investigate differences in permeability related with these different approaches for delivering inhalable formulations onto epithelial air-liquid interfaces.  

Key learning: By investigating optimal conditions to estimate the permeability of inhalable products, Hovione is establishing standards for improving formulation screening with these techniques in the early phases of drug development. 

 

"Understanding Leucine Encapsulation in Dry Powder Inhaler Microparticles via Surface Characterization Techniques"
Authors:
Lídia Santos, Cláudia Costa
Presenter: Cláudia Costa, Ph.D. - R&D Scientist, Advanced Analytical Characterization

Poster brief description: Encapsulation in the DPI formulations were evaluated using specified surface characterization techniques, XPS, IGC and SEM. For XPS analysis the sample preparation and method conditions were previously assessed to assure repeatable and accurate results. The combination of the 3 techniques revealed good insights into the surface composition, shape, and structure of the composite particles. The differences in solubility and molecular structure of the APIs enabled a better understanding of the encapsulation behavior of leucine.

Key Learning: Deep lung delivery of DPI formulations is highly impacted by the cohesion forces between particles. An extensive characterization of the encapsulation process is imperative to achieve a reproducible and repeatable process with good aerosolization performance.

 

HOVIONE ARTICLE - ONdrugDELIVERY

Title: High-dose Delivery Platform For Crystalline DPIs
Authors: Susana Saldanha, Lídia Santos, Rui Churro
Source: OnDrugDelivery, 23 April 2024

Abstract: Respiratory drug delivery has diversified the pipeline and portfolio of diseases that can be treated through this route, including already approved anti-infective medicines for cystic fibrosis or influenza patients, and others in development for pulmonary arterial hypertension, idiopathic pulmonary fibrosis and other rare lung diseases. Also, the doses and molecules delivered to the lungs have increased in the last years from a few micrograms to milligrams. This growth in the delivery of high doses has been observed in pharmaceutical compounds, such as antibiotics, vaccines, proteins and peptides, as well as for the treatment of acute emergency indications via the inhalation route.

Read the full article here 

 

Schedule a meeting with our team and get to know more about our unique range of particle engineering technologies for Inhalation & Nasal such as jet milling, wet milling and spray drying.

 

Let’s discuss your project together.

schedule a meeting

 

Find more about RDD2024

 

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024